Meglumine antimoniate warnings and precautions: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi (talk | contribs) (Created page with "__NOTOC__ {{Meglumine antimoniate}} {{CMG}} <ref>{{Cite web | last = | first = | title = WHO Model Prescribing Information: Drugs Used in Parasitic Diseases - Second E...") |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}} | {{CMG}} | ||
==Warnings and Precautions== | |||
A protein-rich diet should be provided throughout treatment and, where possible, iron depletion and other specific deficiencies should be corrected beforehand. | |||
When possible, both the electrocardiogram and renal and hepatic function should be monitored throughout treatment. Dosage must be reduced should abnormalities occur. | |||
====Use in pregnancy==== | |||
<ref>{{Cite web | last = | first = | title = WHO Model Prescribing Information: Drugs Used in Parasitic Diseases - Second Edition: Protozoa: Leishmaniasis: Meglumine antimoniate and sodium stibogluconate | url = http://apps.who.int/medicinedocs/en/d/Jh2922e/2.4.1.html#Jh2922e.2.4.1 | publisher = | date = | accessdate = }}</ref> | Safe use in pregnancy has not been established. However, because it is potentially fatal, visceral leishmaniasis should always be treated without delay.<ref>{{Cite web | last = | first = | title = WHO Model Prescribing Information: Drugs Used in Parasitic Diseases - Second Edition: Protozoa: Leishmaniasis: Meglumine antimoniate and sodium stibogluconate | url = http://apps.who.int/medicinedocs/en/d/Jh2922e/2.4.1.html#Jh2922e.2.4.1 | publisher = | date = | accessdate = }}</ref> | ||
==References== | ==References== | ||
Latest revision as of 03:42, 7 January 2014
| Meglumine Antimoniate |
|---|
| GLUCANTIM® WHO Prescribing Information |
| Description |
| Indications and Usage |
| Contraindications |
| Warnings and Precautions |
| Adverse Reactions |
| Dosage and Administration |
| How Supplied |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Warnings and Precautions
A protein-rich diet should be provided throughout treatment and, where possible, iron depletion and other specific deficiencies should be corrected beforehand.
When possible, both the electrocardiogram and renal and hepatic function should be monitored throughout treatment. Dosage must be reduced should abnormalities occur.
Use in pregnancy
Safe use in pregnancy has not been established. However, because it is potentially fatal, visceral leishmaniasis should always be treated without delay.[1]
References
Adapted from the FDA Package Insert.